866-997-4948(US-Canada Toll Free)

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 67 Pages

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2017

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System and Other Diseases which include indications Breast Cancer, Asthma, Melanoma, Renal Cell Carcinoma, Acute Inflammation, Autoimmune Disorders, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Cutaneous T-Cell Lymphoma, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Solid Tumor, Ulcerative Colitis, West Nile Virus Infections and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Toll Like Receptor 3 (CD283 or TLR3) - Overview 6
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development 23
Bioncotech Therapeutics SL 23
Hemispherx Biopharma Inc 23
MultiCell Technologies Inc 24
Oncovir Inc 24
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles 26
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BO-112 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CU-CPT4a - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
MCT-465 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
P-7 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Poly-ICLC - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
PrEP-001 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
PRV-300 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
rintatolimod - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products 52
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products 55
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones 56
Featured News & Press Releases 56
Aug 14, 2017: Hemispherx Human Safety Study of Intranasal Ampligen with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated 56
Aug 08, 2017: Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 57
Jul 10, 2017: Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer 58
May 31, 2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities 58
May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology 59
May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017 60
Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017 60
Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharms PrEP-001 as a potential prophylactic against the common cold 60
Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe 62
Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients 63
Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME 63
Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone 63
Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHIs 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA 64
Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic 64
Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indications, H2 2017 9
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Bioncotech Therapeutics SL, H2 2017 23
Pipeline by Hemispherx Biopharma Inc, H2 2017 23
Pipeline by MultiCell Technologies Inc, H2 2017 24
Pipeline by Oncovir Inc, H2 2017 25
Dormant Products, H2 2017 52
Dormant Products, H2 2017 (Contd..1), H2 2017 53
Dormant Products, H2 2017 (Contd..2), H2 2017 54
Discontinued Products, H2 2017 55

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Molecule Types, H2 2017 21
Number of Products by Stage and Molecule Types, H2 2017 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *